(1S,2S)-硼替佐米 | 1132709-14-8

• 物质功能分类: 分析化学 - 标准品 - 药典标准品和杂质标准品
• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: (1S,2S)-硼替佐米
• 中文别名: （1S，2S）-硼替佐米；硼替佐米杂质E
• 英文名称: bortezomib
• 英文别名: ((S)-3-Methyl-1-((S)-3-phenyl-2-(pyrazine-2-carboxamido)propanamido)butyl)boronic acid；[(1S)-3-methyl-1-[[(2S)-3-phenyl-2-(pyrazine-2-carbonylamino)propanoyl]amino]butyl]boronic acid
• CAS: 1132709-14-8
• 化学式: C₁₉H₂₅BN₄O₄
• 分子量: 384.243
• InChiKey: GXJABQQUPOEUTA-DOTOQJQBSA-N

物化性质

• 密度：
  1.214±0.06 g/cm3(Predicted)
• 溶解度：
  DMSO：50 mg/mL（130.13 mM；需要超声波）

计算性质

• 辛醇/水分配系数(LogP)：
  0.36
• 重原子数：
  28
• 可旋转键数：
  9
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.37
• 拓扑面积：
  124
• 氢给体数：
  4
• 氢受体数：
  6

安全信息

• 海关编码：
  2934999090
• 储存条件：
  存放温度应保持在2-8°C，需置于干燥处并密封保存。

制备方法与用途

生物活性 (1S,2S)-Bortezomib 是 Bortezomib 的对映异构体。Bortezomib 是一种细胞渗透性、可逆性和选择性的蛋白酶体抑制剂，通过靶向苏氨酸残基有效抑制 20S 蛋白酶体 (Ki 为 0.6 nM)。它能够破坏细胞周期、诱导细胞凋亡以及抑制核因子 NF-κB。Bortezomib 是一种抗癌药物，也是第一种用于人类的蛋白酶体抑制剂。

靶点 Ki: 0.6 nM (20S 蛋白酶体)

用途 (1S,2S)-Bortezomib 是 Bortezomib 的一种对映异构体，作为一种蛋白酶体抑制剂。研究显示，它能有效抑制某些丝氨酸蛋白酶，从而降低细胞内 β-淀粉样蛋白（Aβ）的浓度，这与阿尔茨海默病或高血压有关。

反应信息

• 作为产物：
  描述：

  L-苯基丙氨酸叔丁酯 在 盐酸 、 异丁基硼酸 、 O-(benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium tetrafluoroborate 、 N,N-二异丙基乙胺 、 N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate 作用下， 以 1,4-二氧六环 、 甲醇 、 正庚烷 、 二氯甲烷 为溶剂， 反应 32.16h， 生成 (1S,2S)-硼替佐米
  参考文献：
  名称：

  用于探测体外生物学的选择性LONP1抑制剂的基于结构的设计

  摘要：

  LONP1是一种AAA +蛋白酶，可通过去除受损或错误折叠的蛋白质来维持线粒体的体内平衡。LONP1的活性和表达升高会促进癌细胞的增殖和对凋亡诱导剂的抗性。尽管LONP1在人类生物学和疾病中很重要，但文献中几乎没有描述过LONP1抑制剂。在这里，我们报告使用基于结构的药物设计以及结合各种抑制剂的人LONP1的第一个结构的选择性硼酸基LONP1抑制剂的发展。我们的努力导致了几种对20S蛋白酶体几乎没有活性的纳米摩尔LONP1抑制剂，它们是研究LONP1生物学的工具化合物。

  DOI：

  10.1021/acs.jmedchem.0c02152

文献信息

• Asymmetric Synthesis of α-Aminoboronates via Rhodium-Catalyzed Enantioselective C(sp³)–H Borylation
  作者：Ronald L. Reyes、Miyu Sato、Tomohiro Iwai、Masaya Sawamura

  DOI：10.1021/jacs.9b12013

  日期：2020.1.8

  α-Aminoboronic acids, isostructural boron analogues of α-amino acids, have received much attention because of the important biomedical applications implicated for compounds containing this structure. Additionally, the inherent versatility of α-aminoboronic acids as synthetic intermediates through diverse carbon-boron bond transformations make the efficient synthesis of these compounds highly desirable

  α-氨基硼酸是α-氨基酸的同构硼类似物，由于含有这种结构的化合物在生物医学上的重要应用而受到广泛关注。此外，α-氨基硼酸通过多种碳-硼键转化作为合成中间体的固有多功能性使得这些化合物的有效合成非常理想。在这里，我们提出了一种 Rh-单亚磷酸酯手性催化体系，该体系能够对包括 2-(N-烷基氨基)杂芳基和 N-烷酰基或芳酰基在内的一系列底物类别的 N-相邻 C(sp3)-H 键进行高效的对映选择性硼基化-基仲或叔酰胺，其中一些是药剂或相关化合物。已经证明了对映体富集的 α-氨基硼酸盐的各种立体定向转化，包括 Suzuki-Miyaura 与芳基卤化物的偶联以及与 α-氨基酸的异氰酸酯衍生物的 Rh 催化反应，从而提供了一种新的肽链延长方法。作为这项工作的一个亮点，硼化方案成功地应用于催化剂控制的位点和立体选择性 C(sp3)-H 无保护二肽化合物的硼化反应，从而显着简化了抗癌药物分子硼替佐米的
• [EN] PROTEASOME INHIBITORS AND PROCESSES FOR THEIR PREPARATION, PURIFICATION AND USE<br/>[FR] INHIBITEURS DU PROTÉASOME ET LEURS PROCÉDÉS DE PRÉPARATION, D'ÉPURATION ET D'UTILISATION
  申请人：CEPHALON INC

  公开号：WO2011087822A1

  公开（公告）日：2011-07-21

  The invention provides boronic esters of Formula (I) wherein R1, R2, R3, and R4 are as described herein, and methods for the preparation and purification thereof.

  该发明提供了式（I）的硼酯，其中R1、R2、R3和R4如本文所述，并提供了其制备和纯化方法。
• Design, Synthesis, Biological Evaluation, and Structure−Activity Relationship (SAR) Discussion of Dipeptidyl Boronate Proteasome Inhibitors, Part I: Comprehensive Understanding of the SAR of α-Amino Acid Boronates
  作者：Yongqiang Zhu、Xin Zhao、Xinrong Zhu、Gang Wu、Yuejie Li、Yuheng Ma、Yunxia Yuan、Jie Yang、Yang Hu、Li Ai、Qingzhi Gao

  DOI：10.1021/jm9005093

  日期：2009.7.23

  New series of dipeptidyl boronate inhibitors of 20S proteasome were designed and synthesized, The comprehensive understanding or the SAR was obtained by utilizing the variation of four substituents. From the screened compounds in enzyme, novel inhibitors 49 and 50 were identified to be highly potent druglike candidates with IC50 values of 1.2 and 1.6 nM, respectively, which showed better activities than the drug bortezomib on the market. Two hematologic human tumor cell lines, HL-60 and U266, were significantly sensitive to both candidates and showed nearly the same potency as the standard bortezomib with IC50 values less than 10 nM. But as for most of the eight human solid tumor cell lines, both candidates were more potent than the standard with the IC50 value range of 9.8-70 nM. The activity evaluation of the stereoisomers showed that changing R-isomers to S-isomers greatly reduced the potency and even induced inactivity.
• Further characterization of a putative serine protease contributing to the γ-secretase cleavage of β-amyloid precursor protein
  作者：Marine Peuchmaur、Marie-Agnès Lacour、Jean Sévalle、Vincent Lisowski、Youness Touati-Jallabe、Fabien Rodier、Jean Martinez、Frédéric Checler、Jean-François Hernandez

  DOI：10.1016/j.bmc.2012.11.045

  日期：2013.2

  The 3-alkoxy-7-amino-4-chloro-isocoumarins JLK-6 and JLK-2 have been shown to markedly reduce the production of Amyloid beta-peptide (A beta) by Amyloid-beta Precursor Protein (APP) expressing HEK293 cells by affecting the gamma-secretase cleavage of APP, with no effect on the cleavage of the Notch receptor. This suggested that these compounds do not directly inhibit the presenilin-dependent gamma-secretase complex but more likely interfere with an upstream target involved in gamma-secretase-associated pathway. The mechanism of action of these compounds is unknown and there are high fundamental and therapeutical interests to unravel their target. Isocoumarin compounds were previously shown to behave as potent mechanism-based irreversible inhibitors of serine proteases, suggesting that the JLK-directed target could belong to such enzyme family. To get further insight into structure-activity relationships and to develop more potent isocoumarin derivatives, we have synthesized and evaluated a series of isocoumarin analogues with modifications at positions 3, 4 and 7. In particular, the 7-amino group was substituted with either acyl, urethane, alkyl or aryl groups, which could represent additional interaction sites. Altogether, the results highlighted the essential integrity of the 3-alkoxy-7-amino-4-chloro-isocoumarin scaffold for A beta-lowering activity and supported the involvement of a seri ne protease, or may be more generally, a serine hydrolase. The newly reported 7-N-alkyl series produced the most active compounds with an IC50 between 10 and 30 mu M. Finally, we also explored peptide boronates, a series of reversible serine protease inhibitors, previously shown to also lower cellular A beta production. The presented data suggested they could act on the same target or interfere with the same pathway as isocoumarins derivatives. (C) 2012 Elsevier Ltd. All rights reserved.
• Structure-Based Design of Selective LONP1 Inhibitors for Probing <i>In Vitro</i> Biology
  作者：Laura J. Kingsley、Xiaohui He、Matthew McNeill、John Nelson、Victor Nikulin、Zhiwei Ma、Wenshuo Lu、Vicki W. Zhou、Mari Manuia、Andreas Kreusch、Mu-Yun Gao、Darbi Witmer、Mei-Ting Vaillancourt、Min Lu、Sarah Greenblatt、Christian Lee、Ajay Vashisht、Steven Bender、Glen Spraggon、Pierre-Yves Michellys、Yong Jia、Jacob R. Haling、Gérald Lelais

  DOI：10.1021/acs.jmedchem.0c02152

  日期：2021.4.22

  of LONP1 in human biology and disease, very few LONP1 inhibitors have been described in the literature. Herein, we report the development of selective boronic acid-based LONP1 inhibitors using structure-based drug design as well as the first structures of human LONP1 bound to various inhibitors. Our efforts led to several nanomolar LONP1 inhibitors with little to no activity against the 20S proteasome

  LONP1是一种AAA +蛋白酶，可通过去除受损或错误折叠的蛋白质来维持线粒体的体内平衡。LONP1的活性和表达升高会促进癌细胞的增殖和对凋亡诱导剂的抗性。尽管LONP1在人类生物学和疾病中很重要，但文献中几乎没有描述过LONP1抑制剂。在这里，我们报告使用基于结构的药物设计以及结合各种抑制剂的人LONP1的第一个结构的选择性硼酸基LONP1抑制剂的发展。我们的努力导致了几种对20S蛋白酶体几乎没有活性的纳米摩尔LONP1抑制剂，它们是研究LONP1生物学的工具化合物。